The Pharmaceutical Year that was, 2024: The Pharmaceutical Year that was, 2024

The efficacy of the vaccine was robust in that it was seen at both seasonal and standard (i.e., perennial) study sites [1]. The CRISPR technique is used to disable the gene, and the stem cells are then auto-transfused, with the intention of increasing the HbF content of the patient's erythrocytes. The parties had agreed to the US$6 billion settlement, and the US Court of Appeals had also given its blessing [9]. [...]this year, the US Supreme Court stepped in, at the behest of the US Department of Justice, suggesting that the protections against yet further litigation were DX 'unprecedented', and that the settlement was, essentially, a bankruptcy manoeuvre.